Brought to you by 
Boehringer to further develop DeveloGen's metabolic program
11 Dec 2015
Executive Summary
Boehringer Ingelheim has agreed to further develop and acquire worldwide rights to a set of compounds discovered by DeveloGen AG (primarily metabolic disease drug discovery) for diabetes, obesity, metabolic syndrome (which includes hypertension, hyperglycemia, and other health problems that increase the risk for heart disease and diabetes), and conditions related to insulin resistance.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boehringer to further develop DeveloGen's metabolic program
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice